Felix Broecker

Felix Broecker is an accomplished professional in the fields of biochemistry and biotechnology, currently serving as the Head of Laboratory at Idorsia Pharmaceuticals Ltd since September 2019. Their expertise includes a strong background in vaccine research, highlighted by roles as a Postdoctoral Fellow at the Icahn School of Medicine at Mount Sinai, focusing on a universal vaccine against influenza, and as a PhD student at the Max Planck Institute of Colloids and Interfaces, developing a glycan-based vaccine for Clostridium difficile. Additional experience includes a position as Technical Manager Pharmacy at the Vaccination Center ICC Berlin and various research roles at institutions such as the University of Zurich and the Max Planck Institute for Molecular Genetics, contributing to studies on targeted therapies for hepatitis C and HIV, as well as the impact of human endogenous retroviruses. Felix Broecker holds a Ph.D. in Biochemistry from Freie Universität Berlin and a Dipl.-Ing. in Biotechnology from Technische Universität Berlin.